Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-12-09 DOI:10.1111/1744-9987.14094

Kenichi Ito, Tomoki Kawasaki, Kazuhiko Hirano, Naohiro Sekiguchi

引用次数: 0

Abstract

Hyperviscosity syndrome (HVS) is a significant complication in Waldenström's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study.

查看原文本刊更多论文

瓦尔登斯特伦巨球蛋白血症伴高粘稠度综合征治疗程序的有效性和安全性

高粘滞性综合征（HVS）是瓦尔登斯特伦巨球蛋白血症（WM）的一种重要并发症，但在临床实践中进行血浆置换的意义尚未明确。为了证实血浆置换后对伴有 HVS 的 WM 进行初级治疗的有效性和安全性，我们回顾性地开展了这项研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.